India's first mRNA Covid-19 vaccine gets nod to start phase 1 trials
The
Central Drugs Standard Control Organisation on Wednesday permitted Pune-based Gennova Biopharmaceuticals to conduct
Phase 1/2 clinical trials, along with animal toxicity data, for its mRNA Covid-19 vaccine candidate.
It is
India's first messenger RNA (mRNA) Covid vaccine candidate. Globally, US-based
pharma giant Pfizer Inc has developed its mRNA vaccine.
The
permission was granted after the Subject expert Committee (SEC) for vaccines
recommended for grant of permission in a review meeting on Wednesday, a
document carrying the recommendations and accessed by IANS showed.
"After
detailed deliberation, the committee recommended for grant of permission to
conduct Phase 1/2 clinical trial subject to the condition that the interim
results of Phase 1 study shall be submitted to the committee before proceeding
to the next phase," the document read. Read More
Comments
Post a Comment